This site is intended for UK healthcare professionals
The licence for Januvia (sitagliptin) has been extended to include two additional uses in patients with type II diabetes.
Januvia is now indicated to improve glycaemic control in combination with a sulfonylurea when diet and exercise plus maximal tolerated dose of a sulfonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindication or intolerance.
It is also indicated for triple therapy in combination with a sulfonylurea and metformin when diet and exercise plus dual therapy with these agents do not provide adequate glycaemic control.
Further information: MSD
The most up-to-date drug information at your fingertips.
EXCLUSIVE TO SUBSCRIBERS See the latest products removed...
Use our constantly updated shortages tracker to check...
EXCLUSIVE TO SUBSCRIBERS See the latest products added...
MIMS Learning is hosting a free webinar on 13 June...
Drugs
Conditions
News and resources
MIMS Hosted